Two landmark trials give CVD outcomes for diabetes drugs

Results for linagliptin and dapagliflozin

Two trials looking at cardiovascular and renal outcomes in patients on therapy for type 2 diabetes will help doctors tailor treatment better to the patient, a diabetes specialist says.

In the CARMELINA international randomised controlled trial, nearly 7000 patients with type 2 diabetes, high cardiovascular risk and high renal risk, were randomised to the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin 5mg once-a-day or to placebo.

Over a median follow-up of 2.2 years, linagliptin (Trajenta, Boehringer Ingelheim) was not inferior to placebo for